MAYNE Pharma has announced that it has received further correspondence from Cosette alleging breaches of misleading or deceptive conduct relating to the FDA concerns around its Nextstellis contraceptive pill (PD 19 Jun).

This is the third such notice, with Cosette stating that it intends to terminate its plan to take over Mayne if the circumstances giving rise to the alleged breach continue to exist for five business days.

Mayne maintains there is no new information and the deal can go ahead as planned.

The post Mayne announces Cosette update appeared first on Pharmacy Daily.